Overview
Opioid abuse and addiction (e.g., heroin, OxyContin) remains a critical national public health concern. In 2002, tablet formulations of the medication Buprenorphine were approved by the Food and Drug Administration for the treatment of opioid addiction. In order to prepare the field to effectively integrated this new treatment, the Buprenorphine Treatment Blending Team developed an awareness training to disseminate information and enhance awareness among multidisciplinary (non-physician) addiction professionals about Buprenorphine treatment. This training is designed to provide a broad overview of the medication, its effects, and the role of non-physician practitioners in providing and supporting the treatment of individuals receiving this medication.
To obtain an overview of the Buprenorphine Treatment Blending product, download the brochure.
Blending Product Materials (download now!)
Buprenorphine Treatment Blending Team Members
NIDA
Leslie Amass, Ph.D. – Friends Research Institute, Inc.
Gregory Brigham, Ph.D. – Maryhaven Community Treatment Program
Eric Strain, M.D. – Johns Hopkins University
SAMHSA/CSAT-ATTC
Thomas Freese, Ph.D. – Pacific Southwest ATTC (Chair)
Glenda Clare, M.A. – Central East ATTC
Beth Finnerty, M.P.H. – Pacific Southwest ATTC
Gail Dixon, M.A. - Southern Coast ATTC
